

Epizyme Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 18-Feb-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 8

Product Portfolio Drugs..... 11

[Return to Table of Contents](#)

Epizyme Inc

COMPANY OVERVIEW

Company Name	Epizyme Inc
Parent Company Name	Epizyme Inc
Website	http://www.epizyme.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	0
Number of Patents as Owner	11
Number of Patents as Third Party	3
Number of Deals	8
Key Indications	Cancer,Non-Hodgkin lymphoma,Acute lymphoblastic leukemia,Acute myelogenous leukemia,Sarcoma,Leukemia,Neurological disease,Diffuse large B-cell lymphoma,Follicle center lymphoma,Hematological neoplasm
Key Target-based Actions	Enhancer of zeste homolog 2 inhibitor,Histone H3 K79 methyltransferase inhibitor,Histone lysine methyltransferase inhibitor,Methyltransferase inhibitor,WHSC1 gene inhibitor,AMP activated protein kinase modulator,Beta adrenoceptor modulator,CLK4 protein kinase inhibitor,DNA polymerase inhibitor,Flt3 tyrosine kinase inhibitor,Glucocorticoid agonist,JMJD1A gene modulator,PCSK9 gene inhibitor,PDGF receptor alpha antagonist,PPAR alpha modulator,PPAR gamma coactivator 1-alpha modulator,Proprotein convertase PC9 inhibitor,Ros1 tyrosine kinase receptor inhibitor,Topoisomerase II inhibitor,TrkA receptor antagonist,TrkC receptor antagonist
Key Technologies	Small molecule therapeutic,Oral formulation,Systemic formulation unspecified,Drug screening,Drug combination,PCR based technology,Antibody,Condensational synthesis,Crystalline form,Gene transfer system,Genetic screening,Humanized antibody,Immunodetection,Immunofluorescence,Intravenous formulation,Liposome formulation,Oligonucleotide,Peptide,Salt

COMPANY PROFILE

SUMMARY

Epizyme Inc was established in 2007 and is focused on the development of drugs based on epigenetics.

FINANCIAL

In February 2014, the company announced an underwritten public offering of 4,192,679 shares. The offering was expected to contain 3,000,000 shares to be offered by Epizyme and 1,192,679 shares to be offered by existing stockholders. At that time, underwriters were expected to be granted a 30-day option to purchase up to 628,901 additional shares; later that month, the offering was priced at \$29.25 per share and the underwriters were a 30-day option to purchase up to 673,901 additional shares; later that month, the offering was closed.

In December 2013, the company was selected for addition to the NASDAQ Biotechnology Index, effective from December 23, 2013. At that time, the common stock was expected to be transferred to the NASDAQ Global Select Market, effective January 02, 2014.

In June 2013, the company was added to Russell 2000, Russell 3000 and Russell Global indexes.

In June 2013, Epizyme closed its initial public offering of 5,913,300 shares of its common stock at a public offering price of \$15.00 per share, before underwriting discounts, including 771,300 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the same price to cover over-allotments. At that time, the company expected net proceeds of approximately \$79.8 million. Later that month, the company raised net proceeds of \$82.5 million from the offering.

[Return to Table of Contents](#)



In April 2013, Epizyme filed a registration statement on Form S-1 with the US Securities and Exchange Commission relating to the proposed initial public offering of common stock; at that time, the company had not determine the number of shares and the price range for the offering. In May 2013, Epizyme priced its IPO of 5,142,000 common stock shares at \$15 per share. The underwriters were also granted a 30-day overallotment option to purchase up to an additional 771,300 common stock shares. The offering was expected to close on June 05, 2013 and at that time, the shares were scheduled to begin trading on the NASDAQ Global Market on May 31, 2013 under the ticker symbol 'EPZM'. In June 2013, the offering closed. The underwriters exercised in full the overallotment purchase option; the company expected to raise net proceeds of approximately \$79.8 million. In December 2013, NASDAQ reported that, Epizyme would be added to the NASDAQ Biotechnology Index, as a result of the annual re-ranking, which would become effective prior to market open on December 23, 2013.

In February 2008, the company raised \$14 million from a series A financing round.


In October 2009, the company raised \$32 million in a series B financing round. In December 2009, the company raised a further \$8 million from a second closing of the series B financing round, bringing the total raised to \$40 million.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	0	3
Hematological disease	2	0	2
Immune disorder	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 1 Clinical	2
Discovery	1

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	1	0	1	0	2
Drug - Funding	2	0	0	0	2
Drug - Development/Commercialization License	3	0	0	0	3
Drug - Development Services	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Hematological disease	2	3

[Return to Table of Contents](#)

Neoplasm	2	3
Immune disorder	1	2

Trials by Phase

Phase	Ongoing	All
Phase 2	1	1
Phase 1	1	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	0	3	3
Endocrine disease	1	2	3
Gastrointestinal disease	0	2	2
Growth disorder	1	0	1
Hematological disease	6	0	6
Immune disorder	4	1	5
Musculoskeletal disease	0	1	1
Neoplasm	12	1	13
Ocular disease	0	1	1
Genetic disorder	1	0	1
Metabolic disorder	0	3	3
Neurological disease	5	1	6
Nutritional disorder	0	1	1
Respiratory disease	0	1	1
Inflammatory disease	0	1	1

[Return to Table of Contents](#)

Gynecology and obstetrics	1	0	1
Dermatological disease	2	1	3

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

EPZ-5676

Drug Name	EPZ-5676
Key Synonyms	
Originator Company	Epizyme Inc
Active Companies	Celgene Corp, Epizyme Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Acute lymphoblastic leukemia, Acute myelogenous leukemia
Target-based Actions	Histone H3 K79 methyltransferase inhibitor
Other Actions	Anticancer, Apoptosis stimulator, Synergist
Technologies	Systemic formulation unspecified, Small molecule therapeutic
Last Change Date	30-Jan-2014

E-7438

Drug Name	E-7438
Key Synonyms	
Originator Company	Epizyme Inc
Active Companies	Eisai Co Ltd, Epizyme Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Non-Hodgkin lymphoma, Sarcoma
Target-based Actions	Enhancer of zeste homolog 2 inhibitor, Histone lysine methyltransferase inhibitor
Other Actions	Synergist, Anticancer
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	09-Jan-2014

[Return to Table of Contents](#)



histone methyltransferase inhibitors (cancer), Epizyme/GlaxoSmithKline

Drug Name	histone methyltransferase inhibitors (cancer), Epizyme/GlaxoSmithKline
Key Synonyms	
Originator Company	Epizyme Inc
Active Companies	GlaxoSmithKline plc, Epizyme Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Methyltransferase inhibitor, WHSC1 gene inhibitor
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	09-Jan-2014

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)